Biotech start-up pockets $8.7M in venture cash

Cellumen says it will use an $8.7 million injection of venture capital to begin its commercialization efforts. The company specializes in cellular systems biology for drug discovery work. Safeguard Scientifics provided $6 million of that while PA Early Stage Partners put up $2 million.

- see the release
- read the the Pittsburgh Business Journal report

Related Articles:
Biotech start-ups flush from big venture rounds. Report
Biotech venture funding jumped in '06. Report